Cargando…

DIPG-03. Therapeutic targeting of purine biosynthesis in DIPG

Diffuse intrinsic pontine glioma (DIPG) is an incurable brainstem malignancy in children. Little progress has been made in treating this deadly disease due to its inoperable location and treatments aimed at targets defined in adult gliomas. Currently there are no targeted therapies that significantl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mersich, Ian, Dasgupta, Biplab
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Diffuse Midline Glioma/DIPG
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165052/ http://dx.doi.org/10.1093/neuonc/noac079.060

Ejemplares similares

DIPG-03. THERAPEUTIC TARGETING OF TRANSCRIPTIONAL ELONGATION IN DIFFUSE INTRINSIC PONTINE GLIOMA
por: Katagi, Hiroaki, et al.
Publicado: (2020)

DIPG-74. RE-IRRADIATION OF DIPG: DATA FROM THE INTERNATIONAL DIPG REGISTRY
por: Lafay-Cousin, Lucie, et al.
Publicado: (2020)

DIPG-12. TARGETING EPIGENETIC MODIFIERS TO INDUCE IMMUNE SIGNALING IN DIPG
por: Tetens, Ashley, et al.
Publicado: (2020)

DIPG-16. Evaluation of myeloid component of DIPG microenvironment
por: Mishra, Deepak, et al.
Publicado: (2022)

DIPG-40. TARGETING MASTER REGULATOR DEPENDENCIES IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Pavisic, Jovana, et al.
Publicado: (2020)

DIPG-46. NON-DIPG PATIENTS ENROLLED IN THE INTERNATIONAL DIPG REGISTRY: HISTOPATHOLOGIC EVALUATION OF CENTRAL NEURO-IMAGING REVIEW
por: Lazow, Margot A, et al.
Publicado: (2020)

DIPG-52. Activators of the integrated stress response synergize to kill DIPG
por: Novak, Orlandi, et al.
Publicado: (2022)

DIPG-20. DETERMINATION AND MANAGEMENT OF HYDROCEPHALUS IN PATIENTS WITH DIPG, AN INSTITUTIONAL EXPERIENCE
por: Fonseca, Adriana, et al.
Publicado: (2020)

DIPG-70. DISORDERED DNA METHYLATION IN DIPG UNDERLIES PHENOTYPIC PLASTICITY
por: Koldobskiy, Michael, et al.
Publicado: (2020)

DIPG-59. UPREGULATION OF PRENATAL PONTINE ID1 SIGNALING IN DIPG
por: Harris, Micah K, et al.
Publicado: (2020)

DIPG-57. TRANSCRIPTOMIC AND PROTEOMIC ANALYSES OF DIPG RESPONSE TO ONC201
por: Sridharan, Sreepradha, et al.
Publicado: (2020)

DIPG-23. SINGLE CASE REPORT OF LOW DOSE RADIOTHERAPY AND CHEMOTHERAPY IN THE TREATMENT OF DIPG
por: Tseng, Chen Kan, et al.
Publicado: (2020)

DIPG-37. Exploring the role of the epigenetic factor H2A.Z acetylation in DIPG
por: Sanguino, Yolanda Colino, et al.
Publicado: (2022)

DIPG-56. EXPLORATION OF TUMOR/STROMA INTERACTIONS IN DIPG XENOGRAFT BY SPECIES-SPECIFIC RNA-SEQ DECONVOLUTION INDICATES A ROLE OF MICROGLIA CELL IN DIPG DEVELOPMENT
por: Merlevede, Jane, et al.
Publicado: (2020)

DIPG-13. TARGETING HYPOXIA AND MITOCHONDRIA WITH REPURPOSED METABOLIC DRUGS AS AN APPROACH TO RADIOSENSITIZATION FOR DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPG)
por: Shen, Han, et al.
Publicado: (2020)

DIPG-73. SENESCENCE ASSOCIATED SECRETORY PHENOTYPE AS A MECHANISM OF RESISTANCE AND THERAPEUTIC VULNERABILITY IN BMI1 INHIBITOR TREATED DIPG
por: Balakrishnan, Ilango, et al.
Publicado: (2020)

DIPG-27. Behavioral disturbances as underestimated presenting symptoms in children with Diffuse Intrinsic Pontine Glioma (DIPG)
por: Milanaccio, Claudia, et al.
Publicado: (2022)

DIPG-21. DIPG cells alter the permeability of the blood-brain barrier in the brainstem leading to treatment failure.
por: Ung, Caitlin, et al.
Publicado: (2022)

DIPG-28. REPEATED LOW DOSE RT FOR PEDIATRIC DIPG – LESS DISEASE BURDEN WITH COMPARABLE OUTCOMES
por: Wu, Yao Yu, et al.
Publicado: (2020)

DIPG-32. AKT SIGNALING DRIVES RESISTANCE TO ONC201 IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Jackson, Evangeline R, et al.
Publicado: (2020)

DIPG-20. Copper chelation therapy targets S-adenosylmethionine (SAM) metabolism and epigenetic regulators in diffuse intrinsic pontine glioma (DIPG)
por: Michniewicz, Filip, et al.
Publicado: (2022)

DIPG-83. USING COPPER CHELATING AGENTS TO TARGET RECEPTOR TYROSINE KINASE SIGNALLING IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Michniewicz, Filip, et al.
Publicado: (2020)

DIPG-53. CHARACTERIZING THE ROLE OF PPM1D MUTATIONS IN THE PATHOGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGS)
por: Khadka, Prasidda, et al.
Publicado: (2020)

DIPG-16. COMBINATION OF ARGININE DEPLETION AND POLYAMINE INHIBITION AS AN ANTICANCER STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Khan, Aaminah, et al.
Publicado: (2020)

DIPG-14. TARGETING POLO-LIKE KINASE 1 IN COMBINATION WITH KEY ONCOGENIC DRIVERS IN DIPG: FROM SINGLE AGENT TO COMBINATION STRATEGIES
por: Franshaw, Laura, et al.
Publicado: (2020)

DIPG-38. ADDITION OF MULTIMODAL IMMUNOTHERAPY TO COMBINATION TREATMENT STRATEGIES FOR CHILDREN WITH DIPG: FINAL RESULTS OF A COHORT OF CHILDREN
por: Van Gool, Stefaan, et al.
Publicado: (2020)

DIPG-07. HIGH THROUGHPUT DRUG SCREENING IDENTIFIES POTENTIAL NEW THERAPIES FOR DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGs)
por: Upton, Dannielle, et al.
Publicado: (2020)

DIPG-39. NOVEL PROTEOMIC ANALYSIS REVEALS EPIGENETIC THERAPEUTIC TARGETS IN PEDIATRIC GLIOMA
por: Li, Daphne, et al.
Publicado: (2020)

DIPG-18. Evaluating drug distribution in children with diffuse intrinsic pontine glioma (DIPG) treated with convection-enhanced drug delivery
por: Szychot, Elwira, et al.
Publicado: (2022)

DIPG-42. TOWARD MULTIMODALITY THERAPY FOR DIPG/DMG: DEVELOPMENT AND INVESTIGATION OF CRANIOSPINAL IRRADIATION AND CONVECTION-ENHANCED DELIVERY PDX MODELS
por: Knox, Aaron J, et al.
Publicado: (2020)

DIPG-71. SELECTIVE HDAC INHIBITOR RG2833 INDUCES DIPG CELL DEATH VIA DOWNREGULATION OF THE NFĸB PATHWAY
por: Barnett, Katherine, et al.
Publicado: (2020)

DIPG-50. Bioinformatic evaluation of genes involved in sphingomyelin biosynthesis in Diffuse Midline Glioma H3K27 altered/DIPG: dysregulation of sphingosine 1-phosphate (SP1)
por: Humphreys, Aimee, et al.
Publicado: (2022)

DIPG-02. Role of a Bevacizumab-based regime in the treatment of children with diffuse intrinsic pontine glioma (DIPG): a systematic review
por: Evans, Mia, et al.
Publicado: (2022)

DIPG-26. THERAPEUTIC EFFECTS OF RADIOTHERAPY WITH CONCOMITANT AND ADJUVANT TEMOZOLOMIDE VERSUS RADIOTHERAPY WITH CONCOMITANT TEMOZOLOMIDE ALONE IN CHILDREN WITH DIPG: A SINGLE-CENTER EXPERIENCE WITH 82 CASES
por: Lai, Mingyao, et al.
Publicado: (2020)

DIPG-27. TARGETING FACILITATES CHROMATIN TRANSCRIPTION (FACT) AS A NOVEL STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) THAT ENHANCES RESPONSE TO HISTONE DEACETYLASE (HDAC) INHIBITION
por: Ehteda, Anahid, et al.
Publicado: (2020)

DIPG-55. PATTERNS OF CEREBROSPINAL FLUID DIVERSION AND SURVIVAL IN CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY
por: Cooney, Tabitha, et al.
Publicado: (2020)

DIPG-49. BRAINSTEM AND PONTINE VOLUMETRIC ANALYSIS AS A SURROGATE MEASURE OF LOCAL DISEASE CONTROL IN CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Bander, Evan D, et al.
Publicado: (2020)

DIPG-62. Reducing the levels of genomic 5-hydroxymethylcytosine by inhibiting the TET pathway induces apoptosis and decreases proliferation in Diffuse Intrinsic Pontine Glioma (DIPG)
por: Parthasarathy, Akhila, et al.
Publicado: (2022)

DIPG-11. DIPGs show robust MHC class I expression but low lymphoid and high myeloid infiltration partly reversible by DNA methyltransferase inhibition
por: Mishra, Deepak, et al.
Publicado: (2022)

DIPG-52. PHASE I CLINICAL TRIAL OF ONC201 IN PEDIATRIC H3 K27M-MUTANT GLIOMA OR NEWLY DIAGNOSED DIPG
por: Gardner, Sharon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ub8mi2e7rksdgqu412r0e4ikpv